Cross sections of the reaction 231Pa(d,3n)230U for the production of 230U/226Th for targeted α therapy

被引:23
|
作者
Morgenstern, A. [1 ]
Lebeda, O. [2 ]
Stursa, J. [2 ]
Capote, R. [3 ]
Sin, M. [4 ]
Bruchertseifer, F. [1 ]
Zielinska, B. [1 ]
Apostolidis, C. [1 ]
机构
[1] Commiss European Communities, Joint Res Ctr, Inst Transuranium Elements, D-76125 Karlsruhe, Germany
[2] Acad Sci Czech Republ, Inst Nucl Phys, Publ Res Inst, CZ-25068 Rez, Czech Republic
[3] IAEA, NAPC Nucl Data Sect, A-1400 Vienna, Austria
[4] Univ Bucharest, Dept Nucl Phys, RO-70709 Bucharest, Romania
来源
PHYSICAL REVIEW C | 2009年 / 80卷 / 05期
关键词
MODEL CODE; EMPIRE;
D O I
10.1103/PhysRevC.80.054612
中图分类号
O57 [原子核物理学、高能物理学];
学科分类号
070202 ;
摘要
U-230 and its daughter nuclide Th-226 are novel therapeutic nuclides for application in targeted alpha therapy of cancer. We investigated the feasibility of producing U-230/Th-226 via deuteron irradiation of Pa-231 according to the reaction Pa-231(d,3n)U-230. The experimental excitation function for a deuteron-induced reaction on Pa-231 is reported for the first time. Cross sections were measured using thin targets of Pa-231 prepared by electrodeposition and U-230 yields were analysed using alpha spectrometry. Beam energies were calculated from measured beam orbits and compared with the values obtained via monitor reactions on aluminium foils using high-resolution gamma spectrometry and IAEA recommended cross sections. Beam intensities were determined using a beam current integrator. The experimental cross sections are in excellent agreement with model calculations allowing for deuteron breakup using the EMPIRE 3 code. According to thick-target yields calculated from the experimental excitation function, the reaction Pa-231(d,3n)U-230 allows the production of U-230/Th-226 at moderate levels.
引用
收藏
页数:6
相关论文
共 48 条